Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly increases Chinese sales by 26 per cent

Eli Lilly says its has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole

US-based pharmaceutical company Eli Lilly has said it has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole.

The company added that it expected to become the tenth largest company in the global pharmaceutical market by 2010. China is expected to become the seventh largest pharmaceutical market in 2012 and the second largest in 2020.

Lilly says it will introduce five drugs to the Chinese market in 2007 and an additional fifteen drugs over the next five years. The company signed an agreement with Hutchison Whampao, a drug development unit owned by Li Ka-shing, for the development of western drugs for treating cancer and inflammation.

18th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics